List view / Grid view
16 May 2014 | By Novo Nordisk
Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists...
12 May 2014 | By Novo Nordisk
Novo Nordisk announced new phase 3 interim data from its guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade...
1 May 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
14 March 2014 | By Novo Nordisk
Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark...
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
18 November 2013 | By Novo Nordisk
NovoEight® has passed the review by the Committee on Drugs of Japan's Pharmaceutical Affairs and Sanitation Council...
1 November 2013 | By Novo Nordisk
FlexTouch® is the latest innovation in prefilled insulin delivery systems from Novo Nordisk...
31 October 2013 | By Novo Nordisk
Sales growth of 8% driven by Victoza®, Levemir® og NovoRapid®...
16 October 2013 | By Novo Nordisk
“The approval of Novoeight® marks an important step in offering a new alternative for people with haemophilia A..."
27 September 2013 | By Novo Nordisk
Data from the DUAL™ I trial show IDegLira demonstrates a statistically significant greater reduction in blood sugar levels (HbA1c) compared to insulin degludec or liraglutide alone...
